Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease

https://doi.org/10.1016/S0006-291X(05)80276-1Get rights and content

Summary

The total sequence data for mitochondrial DNA (mtDNA) revealed distinct clustering of point mutations (pms) in mtDNA among one patient with myoclonus epilepsy with ragged-red fibers (MERRF), two patients with Parkinson's disease (PD), two patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and one patient with fatal infantile cardiomyopathy (FICM). Among 33 to 62 pms found in each patients, sequentially diverged five clusters of pms were detected and designated as C-1 to C-5. C-1, consisted of fourteen pms, existed in the MERRF patient, C-1 and C-2 (nine pms) in one PD patient, C-1 to C-3 (seven pms) in another PD patient, C-1 to C-4 (one pm) in one MELAS patient and C-1 to C-5 (three pms) in another MELAS patient and the FICM patient. From these clustering of pms, a phylogenetic tree of mitochondrial encephalomyopathies (ME) was constructed. This tree clearly indicated that the ME and PD patients are members of the same gene family, and the MELAS and FICM patients are each others' closest relative. Each patient's unique pms (14 to 28 pms) were detected and, from their characteristic features, the types of the mutations specific for the disease were classified as mit + syn for MERRF, mit + p for PD, and syn + mit for MELAS. An inverse relation was found between the total number of pms and life span of the MELAS and FICM patients.

References (30)

  • YonedaM. et al.

    Lancet

    (1989)
  • ShoffnerJ.M. et al.

    Cell

    (1990)
  • OzawaT. et al.

    Biochem. Biophys. Res. Commun.

    (1988)
  • IkebeS. et al.

    Biochem. Biophys. Res. Commun.

    (1990)
  • OzawaT. et al.

    Biochem. Biophys. Res. Commun.

    (1990)
  • FukuharaN. et al.

    J. Neurol. Sci.

    (1980)
  • InoH. et al.

    Lancet

    (1991)
  • TanakaM. et al.

    Lancet

    (1990)
  • TanakaM. et al.

    Biochem. Biophys. Res. Commun.

    (1989)
  • AndersonS. et al.

    J. Mol. Biol.

    (1982)
  • BibbM.J. et al.

    Cell

    (1981)
  • LinnaneA.W. et al.

    Lancet

    (1989)
  • TanakaM. et al.

    Biochem. Biophys. Res. Commun.

    (1991)
  • TzagoloffA.

    Mitochondria

  • WallaceD.C. et al.

    Science

    (1988)
  • Cited by (115)

    • The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects

      2019, Neurochemistry International
      Citation Excerpt :

      Standard Sanger sequencing techniques available during this time were primarily limited to identifying homoplasmic or high-frequency heteroplasmic variants (Howell et al., 2005). A few studies sequenced whole mtDNA (Ikebe et al., 1995; Ozawa et al., 1991), whilst others sequenced all of the mtDNA tRNA (Simon et al., 2000; Grasbon-Frodl et al., 1999; Brown et al., 1996) and rRNA genes (Brown et al., 1996). Furthermore, some employed restriction fragment length polymorphism (RFLP) methods to investigate whether certain mtDNA variants (e.g. m.3397A > G in MT-ND1) associate with PD (Bandmann et al., 1997; Mayr-Wohlfart et al., 1997).

    • Impairment of mitochondrial tRNA<sup>Ile</sup> processing by a novel mutation associated with chronic progressive external ophthalmoplegia

      2011, Mitochondrion
      Citation Excerpt :

      Specifically, an adult patient presenting with CPEO was found to harbor a substitution (m.4308G>A) in the T-stem of mitochondrial tRNAIle that has not been previously observed. To date 14 substitutions in tRNAIle have been linked to mitochondrial diseases: m.4267A>G (Taylor et al., 2002), m.4269A>G (Degoul et al., 1998; Hayashi et al., 1994; Kaido et al., 1995; Taniike et al., 1992), m.4274T>C (Borthwick et al., 2006; Chinnery et al., 1997), m.4284G>A (Corona et al., 2002), m.4285T>C (Silvestri et al., 1996), m.4290T>C (Limongelli et al., 2004), m.4291T>C (Wilson et al., 2004), m.4295A>G (Merante et al., 1996), m.4298G>A (Taylor et al., 1998), m.4300A>G (Casali et al., 1995; Taylor et al., 2003), m.4302A>G (Berardo et al., 2010), m.4309G>A (Campos et al., 2002; Franceschina et al., 1998), m.4317A>G (Degoul et al., 1998; Obayashi et al., 1992; Ozawa et al., 1991a, 1991b; Tanaka et al., 1990) and m.4320C>T (Santorelli et al., 1995). Seven of them are associated with CPEO (in italics) suggesting that tRNAIle could be a hotspot for CPEO.

    • Is there a pathogenic role for mitochondria in Parkinson's disease?

      2009, Parkinsonism and Related Disorders
      Citation Excerpt :

      This striking result was associated with decreased cytochrome c oxidase (i.e. complex IV and not complex I) activity, as evidenced by histochemistry. Aside from the above analyses, sequencing of the mtDNA of patients with PD has generally been done in unselected groups with and without a mitochondrial deficiency [25,26]. Although the results of some reports have suggested increased frequency of specific mtDNA polymorphisms in patients with PD, others have not [27–31].

    • Mitochondria in the aetiology and pathogenesis of Parkinson's disease

      2008, The Lancet Neurology
      Citation Excerpt :

      These results support the proposal that the human substantia nigra is a site of free-radical-mediated damage to mtDNA, and that this damage is enhanced in parkinsonism. Sequencing of the mtDNA of patients with PD has generally been done in unselected groups, with and without a mitochondrial deficiency.25,26 Although the results of some reports have suggested increased frequency of specific mtDNA polymorphisms in patients with PD, this has not been replicated in all studies.27–31

    • Mitochondria in the etiology of Parkinson's disease

      2007, Handbook of Clinical Neurology
    View all citing articles on Scopus
    View full text